Talphera to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
Talphera Inc TLPH
$1.11
▲ +1.83%
(+$0.02)
📅 Earnings This Week
Open
$1.10
Prev Close
$1.09
Day Range
$1.07 – $1.14
52W Range
$0.69 – $1.57
Market Cap
$56.58M
Beta
0.81
EPS (TTM)
$-0.26
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2011-02-11 |
| Shares Out. | 51,910,000 |
| Website | talphera.com ↗ |
| Phone | 18009279800 |
| Employees | 12 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$4.3M |
| Free Cash Flow | -$12.3M |
| Total Assets | $26.8M |
| Total Liabilities | $12.4M |
| Equity | $14.4M |
About Talphera Inc
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Talphera Inc is a publicly traded company under the ticker symbol TLPH on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-11-01)